Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations

Nat Rev Clin Oncol. 2010 Feb;7(2):71-2. doi: 10.1038/nrclinonc.2009.191.
No abstract available

Publication types

  • Comparative Study
  • News

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Erlotinib Hydrochloride
  • Gefitinib
  • Genes, erbB-1 / genetics*
  • Humans
  • Mutation
  • Quinazolines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Erlotinib Hydrochloride
  • Gefitinib